Acutus Medical Inc., of Carlsbad, Calif., reported a $170 million financing, including a $100 million series D equity financing and a $70 million credit facility. The series D equity financing round included new investors 8VC, Opaleye Management, Pura and Vida Investments. The round also included participation from existing investors, including Orbimed, Deerfield Management Company, Advent Venture Partners, Xeraya Capital and GE Ventures. The credit facility was provided by Orbimed Credit and Royalties Fund and Deerfield Management. Proceeds from the financing will allow Acutus to increase market availability of the company's FDA-approved and CE-marked Acqmap products for cardiac imaging, as well as the FDA-cleared, electrophysiology-designed vascular access products Acqcross QX, Acqguide Flex and Acguide Mini.

Medigus Ltd., an Omer, Israel-based developer of minimally invasive tools and direct visualization technology, reported the signing of a definitive agreement with Algomizer Ltd. and its wholly-owned subsidiary Linkury Ltd. for an investment of approximately $5 million in Algomizer Group, a New York and Petah Tikva, Israel-based provider of technology for internet marketing. The investment agreement contains customary provisions and warranties, and provides for Medigus to invest NIS5.4 million (US$1.51 million) directly in Algomizer Ltd. Medigus will invest an additional NIS9 million through a direct acquisition of the shares of Linkury Ltd. from Algomizer, a valuation of approximately NIS96 million. Medigus will further invest an additional $1 million in Algomizer through equity exchange by issuing Algomizer American depositary shares (ADRs) and warrants to purchase ADRs. Algomizer will issue Medigus warrants to purchase Algomizer shares in an amount equal to the shares purchased by Medigus in the transaction. Medigus will hold 17.9% at Algomizer Group and be entitled to appoint two directors to the board of Algomizer.

Personalis Inc., of Menlo Park, Calif., priced its initial public offering of 7,921,500 shares of common stock at $17 per share on the Nasdaq Global Market under the symbol PSNL. All of the shares of common stock are being offered by the cancer genomics company. In addition, Personalis has granted the underwriters a 30-day option to purchase up to an additional 1,188,225 shares of common stock. The offering is expected to close on June 24. Morgan Stanley, BofA Merrill Lynch and Cowen are acting as joint book-running managers; Oppenheimer & Co. Inc. is acting as co-manager for the offering.

Tangen Biosciences Inc., a molecular diagnostic company located in Branford, Conn., said it has closed a $9 million series A equity round led by Connecticut Innovations, with participation of current and new stockholders, including VC23, Axiom and Leading Edge Ventures. The financing proceeds will be used to accelerate the company's innovative platform Tangendx to the clinic for two infectious disease tests.

No Comments